Business
Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference
AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will
About this update from Natera, Inc.
[{"type":"text","content":"AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American Transplant Congress' (ATC) 2021 Virtual Connect, taking place June 4-9, 2021.\n\n \n \n \n \n \n \n\n \nThree posters showcasing the scientific progress and performance of the Prospera test will be presented along with four sponsored presentations featuring leading transplant physicians. \n\"We look forward to sharing our latest findings with the transplant community and believe these innovations will play an important role in helping nephrologists make more timely and informed decisions about the health of their patients' transplanted organs,\" said Bernie Tobin, Natera's general manager of organ health.\nDetails about Natera's symposia are as follows:\nFresh Perspectives on Rejection Assessment with cfDNA | June 5, 1:30 PM ET\nNew Methods to Evaluate Rejection Using Donor Fraction & Dd-cfDNA Quantity\nSuphamai Bunnapradist, M.D., M.S., transplant nephrologist and professor of medicine, University of California, Los AngelesCell-free DNA Performance in Simultaneous Pancreas-Kidney and Pancreas Recipients\nSamy Riad, M.D., M.S., assistant professor of medicine, division of nephrology and hypertension, University of MinnesotaProspera in Action: Kinetics and Routine Surveillance\nDavid Wojciechowski, D.O., medical director, kidney transplantation program, University of Texas Southwestern Rodolfo Batarse, M.D., president & nephrologist, Desert Kidney Care Ty Dunn, M.D., surgical director of kidney & pancreas transplantation, University of PennsylvaniaProspera: The Power & Potential of cell-free DNA in Transplantation & Oncology | June 6, 11:30 AM ET\nHossein Tabriziani, M.D, FACP, FASN, medical director of organ transplantation at Natera, Inc.Details about the abstract presentations are as follows:\nAbstract #LB 76 | Poster Presentation | Presenter: Suphamai Bunnapradist, M.D., M.S.\nDetection of rejection in kidney transplant patients using an algorithm that combines donor fraction and dd-cfDNA quantity\nResults of a study incorporating the dd-cfDNA fraction with the dd-cfDNA quantity shows improved performance of the Prospera test to assess active rejection. The application of these two va...